Compass Therapeutics (CMPX) Free Cash Flow (2018 - 2026)

Compass Therapeutics has disclosed Free Cash Flow across 9 years of filings, most recently posting -$17.4 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$17.4 million, down 31.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$53.3 million (down 20.47% YoY), and the FY2025 annual result was -$49.2 million, down 9.51% from the prior year.
• Free Cash Flow came in at -$17.4 million for Q1 2026 at Compass Therapeutics, down from -$13.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$4.5 million in Q2 2022 to a low of -$17.4 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$11.0 million (2022), against an average of -$11.0 million.
• Across the five-year window, Free Cash Flow slumped 186.85% in 2022 and soared 45.92% in 2023, its largest moves.
• Compass Therapeutics' Free Cash Flow stood at -$10.7 million in 2022, then retreated by 15.6% to -$12.4 million in 2023, then rose by 25.89% to -$9.2 million in 2024, then slumped by 44.66% to -$13.3 million in 2025, then slumped by 30.91% to -$17.4 million in 2026.
• The last three Free Cash Flow figures came in at -$17.4 million (Q1 2026), -$13.3 million (Q4 2025), and -$10.9 million (Q3 2025), per Business Quant data.